Add time:09/29/2019         Source:infona.pl

Gene therapy has been considered as an alternative treatment for glioblastoma therapy. In this study, a glioblastoma‐specific suicide gene, pEpo–NI2–SV–TK, was delivered into the intracranial glioblastoma model using reducible poly(oligo‐d‐arginines) (rPOA). pEpo–NI2–SV–TK has the erythropoietin (Epo) enhancer and the nestin intron 2 (NI2) for glioblastoma specific gene expression. The in vitro studies showed that the rPOA formed stable complexes with pEpo–NI2–SV–TK. In the MTT and TUNEL assays, rPOA showed lower cytotoxicity than polyethylenimine (25 kDa, PEI25k). In addition, the rPOA/pEpo–NI2–SV–TK complex induced higher glioblastoma cell death under hypoxic condition than normoxic condition, suggesting that pEpo–NI2–SV–TK induced gene expression in the hypoxic tumor tissue. For in vivo therapeutic efficacy evaluation, the rPOA/pEpo–NI2–SV–TK complex was injected into the brains of an intracranial glioblastoma rat model. The rPOA/pEpo–NI2–SV–TK injected group had a significantly reduced tumor size, compared with the control and the PEI25k/pEpo–NI2–SV–TK injected group. The TUNEL assay showed that the rPOA–pEpo–NI2–SV–TK complex had more apoptotic cells than the control and PEI25k/pEpo–NI2–SV–TK injected groups. These results suggest that the rPOA is an efficient carrier for pEpo–NI2–SV–TK and increased the therapeutic efficacy in the intracranial glioblastoma models. Therefore, the rPOA/pEpo–NI2–SV–TK complex may be useful for glioblastoma specific gene therapy. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3743–3751, 2015

We also recommend Trading Suppliers and Manufacturers of D(-)-Arginine (cas 157-06-2). Pls Click Website Link as below: cas 157-06-2 suppliers